Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing ...
CSR Wire14h
The Centrifuge Sessions: How Gilead Sciences Is Impacting Autoimmune Disease
Gilead Sciences Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives ...
California Healthline14h
California Healthline Daily Edition
Below, check out the roundup of California Healthline's coverage. For today's national health news, read KFF Health News' Morning Briefing.
Pharmabiz22h
US FDA accepts Gilead’s NDA for twice-yearly lenacapavir for HIV prevention under priority review
Foster City, California Thursday, February 20, 2025, 12:00 Hrs [IST] ...